Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093833 · ClinicalTrials.gov registry record · Phase 1
A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces
A Phase 1 study, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01093833 is a Phase 1 study that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 40 participants.
The verdict
NCT01093833, a Phase 1 study, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two continuous glucose sensors, one placed subcutaneous (under the skin) and one placed intradermal (in the skin) over 12-14 hours.
Interventions
- DEVICE BD Continuous glucose monitor (BD CGM)
- DEVICE YSI Glucose Analyzer
- DEVICE Medtronic Guardian CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093833
The ClinicalTrials.gov registry entry for NCT01093833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BD Continuous glucose monitor (BD CGM) is the first listed.
NCT01093833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093833 about?
NCT01093833 is a clinical study titled "A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces". The purpose of this study is to compare two continuous glucose sensors, one placed subcutaneous (under the skin) and one placed intradermal (in the skin) over 12-14 hours.
What is the current status of trial NCT01093833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT01093833?
The interventions under investigation include: BD Continuous glucose monitor (BD CGM) (DEVICE), YSI Glucose Analyzer (DEVICE), Medtronic Guardian CGM (DEVICE).
Who is sponsoring clinical trial NCT01093833?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.